AC T01840
XX
ID T01840
XX
DT 05.06.1996 (created); ewi.
DT 06.03.2007 (updated); sou.
CO Copyright (C), QIAGEN.
XX
FA WT1 I
XX
SY Swiss-Prot isoform-3; Wilms tumor zinc finger protein; WT-ZFP; WT1 I +KTS; WT1(-/+).
XX
OS human, Homo sapiens
OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates
XX
GE G004120 WT1; HGNC: WT1.
XX
CL C0001; CH; 2.3.3.0.21.3.
XX
SZ 432 AA; 47.5 kDa (cDNA) (calc.).
XX
SQ MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAP
SQ PPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQA
SQ SSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHED
SQ PMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQ
SQ MNLGATLKGHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASET
SQ SEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRH
SQ TGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNM
SQ HQRNMTKLQLAL
XX
SC edited from Swiss-Prot #P19544
XX
FT 1 304 
PF02165; Wilm's tumour protein.
FT 306 330 
PF00096; zf-C2H2.
FT 306 330 
SM00355; c2h2final6.
FT 306 335 
PS50157; ZINC_FINGER_C2H2_2.
FT 336 360 
PF00096; zf-C2H2.
FT 336 360 
SM00355; c2h2final6.
FT 336 365 
PS50157; ZINC_FINGER_C2H2_2.
FT 366 388 
PF00096; zf-C2H2.
FT 366 388 
SM00355; c2h2final6.
FT 366 393 
PS50157; ZINC_FINGER_C2H2_2.
FT 397 421 PF00096; zf-C2H2.
FT 397 421 SM00355; c2h2final6.
FT 397 426 PS50157; ZINC_FINGER_C2H2_2.
XX
SF 4 zinc finger motifs;
SF alternative splice variant lacking 17 AA (250-266 of WT1);
XX
FF associated with splicing factors like isoform T00899 [2];
FF binds to RNA via zinc finger [2];
FF has reduced ability to generate DNase I footprints [3];
XX
IN T06006 p73alpha; monkey, Cercopithecus aethiops.
XX
MX M07436 V$WT1_Q4.
MX M01118 V$WT1_Q6.
MX M02036 V$WT1_Q6_01.
MX M03893 V$WT1_Q6_02.
XX
BS R02307.
BS R02308.
BS R02309.
BS R02310.
BS R02311.
BS R02312.
BS R04858.
BS R04859.
BS R04861.
BS R02262.
XX
DR TRANSPATH: MO000025970.
DR UniProtKB: P19544-3;
XX
RN [1]; RE0002675.
RX PUBMED: 1321494.
RA Bickmore W. A., Oghene K., Little M. H., Seawright A., van Heyningen V., Hastie N. D.
RT Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript
RL Science 257:235-237 (1992).
RN [2]; RE0006498.
RX PUBMED: 7736591.
RA Larsson S. H., Charlieu J.-P., Miyagawa K., Engelkamp D., Rassoulzadegan M., Ross A., Cuzin F., van Heyningen V., Hastie N. D.
RT Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing
RL Cell 81:391-401 (1995).
RN [3]; RE0006666.
RX PUBMED: 8175666.
RA Werner H., Rauscher III F. J., Sukhatme V. P., Drummond I. A., Roberts jr C. T., LeRoith D.
RT Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site
RL J. Biol. Chem. 269:12577-12582 (1994).
RN [4]; RE0049501.
RX PUBMED: 16087727.
RA Reizner N., Maor S., Sarfstein R., Abramovitch S., Welshons W. V., Curran E. M., Lee A. V., Werner H.
RT The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
RL J. Mol. Endocrinol. 35:135-144 (2005).
XX
//